Living with Ozempic-Related Gastroparesis: What Florida Patients Should Know

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Exposure Concerns

If you're experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be facing gastroparesis—a condition where stomach emptying slows dangerously. This concern builds on decades of pharmacovigilance research that has long recognized drug-induced motility disorders. This page reviews the safety signals, symptom patterns, and what medical monitoring involves for Florida patients.

Find Out If You Qualify for Compensation →

Bridging General Knowledge to Ozempic-Specific Risks

Building on the foundation of general health awareness, it is essential to focus on the specific risks associated with Ozempic (semaglutide). Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can, in susceptible individuals, progress to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical diagnosis of gastroparesis typically involves gastric emptying scintigraphy showing delayed emptying after a standardized meal, along with exclusion of other causes. The link between Ozempic and gastroparesis is supported by the drug's known gastrointestinal adverse effect profile. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%), with the majority of reports of nausea, vomiting, and/or diarrhea occurring during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which aligns with the mechanistic pathway of delayed gastric emptying induced by GLP-1 receptor agonists.

Mechanistic Pathway and Clinical Evidence Linking Ozempic to Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptor agonists slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions, which can lead to prolonged retention of gastric contents. In patients with pre-existing gastric dysmotility or those who develop severe delayed emptying, this can manifest as gastroparesis. The timeline between exposure and documented harm varies; gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, progression to full gastroparesis may require longer exposure, and cases have been reported after months of treatment. The discontinuation rate due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (0.5 mg 3.1%, 1 mg 3.8%) compared to placebo (0.4%), reflecting the clinical significance of these effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central issue. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a specific adverse reaction. The label notes that serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported, and caution is advised for patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a direct warning for gastroparesis may be considered inadequate by some, given the mechanistic plausibility and the frequency of gastrointestinal symptoms that can precede or mimic gastroparesis. Patients who develop persistent vomiting, early satiety, or abdominal distension while on Ozempic may not be promptly evaluated for gastroparesis, leading to delayed diagnosis and potential complications such as malnutrition, electrolyte imbalances, and aspiration.

Florida Statute of Limitations and Settlement Considerations

For affected patients in Florida, settlement-related considerations depend on the statute of limitations for product liability claims. In Florida, the statute of limitations for personal injury claims, including those related to defective drugs, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Given that Ozempic was approved by the FDA in 2017, and widespread use began thereafter, the timeline between exposure and documented harm is critical. Patients who developed gastroparesis after starting Ozempic must establish when they first experienced symptoms that could be linked to the drug, as this date triggers the statute of limitations. The settlement landscape for Ozempic-related gastroparesis is evolving, with multidistrict litigation (MDL) pending in federal court. Settlement amounts, if any, will depend on factors such as the severity of the injury, the strength of the causal link, and the adequacy of warnings. Patients should consult with a qualified attorney to assess their individual circumstances and ensure timely filing. In summary, the evidence supports a mechanistic and clinical link between Ozempic and gastroparesis, with gastrointestinal adverse reactions occurring at higher rates in treated patients. The adequacy of warnings is questionable, as gastroparesis is not explicitly listed. Florida's statute of limitations requires prompt action by affected patients, with a four-year window from discovery of injury. Settlement considerations will hinge on the strength of the causal evidence and the timing of harm. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims related to defective drugs is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Patients should consult an attorney promptly to ensure their claim is filed within the applicable time frame.

Is there a direct link between Ozempic and gastroparesis?

Yes, the mechanistic pathway involves Ozempic slowing gastric emptying, which can progress to gastroparesis in susceptible individuals. Clinical trials show a dose-dependent increase in gastrointestinal adverse events, including nausea, vomiting, and dyspepsia, which are consistent with gastroparesis symptoms. However, the prescribing information does not explicitly list gastroparesis as an adverse reaction, which may be considered an inadequate warning.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.